Setting the price at which new oncology treatments are offered requires an appreciation of both the manufacturer's perspective and the capacity that healthcare systems have to absorb treatment costs. This is an increasingly complex task considering the high cost of new oncology treatments and the growing demands placed on limited healthcare resources.
Pricing and Market Access already heads up the list of challenges facing oncology brand and portfolio managers, moreover IMS Oncology experts predict that pricing, reimbursement and market access issues will become even more crucial to the success of oncology brands in the near future.
The following are and will continue to be crucial challenges in the oncology area:
-
Achieving optimum pricing while securing reimbursement and market access for a new product within the shortest amount of time and with a minimum of prescribing restrictions
-
Maintaining the price and reimbursement level of an in-line product throughout its lifecycle.
Through our extensive experience of comprehensive economic evaluations and pricing studies, our pricing and health economics experts can help oncology clients determine appropriate pricing and market access strategies in a variety of country-specific settings.
Our experts have engaged with pharma clients and stakeholders in hundreds of oncology projects—creating global pricing strategies, adapting global studies to local needs, planning and implementing local studies, gathering and packaging data, compiling local dossiers—all leading up to price, reimbursement and listing (formulary, budget -holder) negotiations.
Click to enlarge